So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
Genezen Laboratories Inc. says new funding from a Massachusetts-based private equity firm will allow it to expand its plans for a new production facility in Fishers Crosspoint Business Park.
The state’s new dashboard on COVID-19 vaccines provides interesting breakdowns on who is getting vaccinated, by county, by gender, by race, by age and a host of other statistics sure to please any proud data geek.
The 39 companies that won venture funding represent a wide range of therapeutics, devices and health information technology.
Last week, state health officials said they expected to initially receive 55,575 doses of Pfizer’s COVID-19 vaccine, and had already begun vaccinating front-line health care workers. But just five days later, state officials and hospitals are keeping mum about how many doses they actually received, except to say it was fewer than expected.
Eli Lilly and Co. on Tuesday announced that it is buying New York-based Prevail Therapeutics Inc., an emerging player in the sizzling-hot area of gene therapies, which targets Parkinson’s disease and other brain-related maladies.
Lilly said it will enroll up to 500,000 people in its latest study, with at least 5,000 people expected to receive bamlanivimab therapy. The drugmaker is partnering with health insurer UnitedHealth Group to see if the drug will help high-risk people.
CEO Jeff Simmons said the company’s high-profile downtown Indianapolis headquarters will signal a cultural transformation at the company, which for most of its six decades of existence operated as a little-noticed subsidiary of Eli Lilly and Co.
In every significant statistical category, November has been a record-setter for the COVID-19 pandemic in Indiana, with cases, deaths and hospitalizations far exceeding even the early months of the coronavirus outbreak.
Despite the change in fortunes, Ascension signaled that it is not yet out of the woods, noting that “consumer confidence and healthcare hesitation as a result of COVID-19 continue to affect Ascension markets, to varying degrees.”
The not-for-profit launched in 2013 as a way to bridge the gap between research universities and industry in life sciences. But its report card so far is decidedly mixed, and it just hired its third CEO.
Under the Affordable Care Act, health insurers are required to spend 80% to 85% of the revenue they get from premiums on medical care. If they don’t, they have to issue rebates or credits to make up the difference.
The federal government says readmissions are often unnecessary and cost taxpayers tens of billions of dollars a year for treatments that should have been caught the first time around, or were not followed up adequately.
Indiana lags much of the nation in flu vaccination rates, and some public health officials say the combination of flu and coronavirus illness could overwhelm hospitals this winter.
State statistics reveal a very uneven, lumpy picture for COVID-19 cases from county to county, and the picture is constantly shifting.
A panel of experts spoke at IBJ’s Life Sciences Power Breakfast, which took place virtually Oct. 9, talked about venture capital in the life sciences sector. These are some excerpts.
It’s that time of year, when workers gather in the conference room (or through a zoom video conference) and brace for the latest news on health insurance plans.
The hospital system has filed a petition for vacation of several streets, meaning it wants to close or privatize them and fold them into the new campus.
The layoff is the first step in what is expected to be a major restructuring following Greenfield-based Elanco’s $6.9 billion acquisition of German conglomerate Bayer AG’s animal-health division.
Like many other providers, Ascension suspended all elective, nonessential medical and surgical procedures for several months to prepare for the surge of COVID-19 patients, reducing volume and revenue.
